Hereditary Cancer Mutation and Drug Development

Speaker

Portrait of Pamela Munster, MDPamela Munster, MD
Professor, Department of Medicine (Hematology/Oncology)
Director, Early Phase Clinical Trials Unit
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

About the Speaker

Dr. Pamela Munster is Co-Director of the Center for BRCA Research, a BRCA-focused clinical and research program at the Helen Diller Family Comprehensive Cancer Center at University of California San Francisco (UCSF). She received her medical degree from the University of Bern, Switzerland; completed her residency in Internal Medicine at Indiana University Medical Center then moved to Memorial Sloan-Kettering Cancer Center, New York for her oncology and hematology fellowship. Dr. Munster served at Memorial Sloan Kettering as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute, Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and Co-Chair of the Phase I Program at Moffitt for six years prior to joining UCSF. Currently, Dr. Munster is Professor in Residence at UCSF where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Co-Program Leader of Developmental Therapeutics.

Dr. Munster’s basic laboratory research interests are in the area of developing novel targeted therapies for the treatment of treatment-resistant cancer and their integration into current treatment strategies. Dr. Munster’s research interests involve basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing HDAC inhibitors reverse hormone therapy related to resistance in breast cancer as well as to reengage the immune defense. Dr. Munster’s clinical research interests are in the area of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in germline cancer mutations.

Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research. She recently authored “Twisting Fate: My Journey with BRCA—from Breast Cancer Doctor to Patient and Back.” For more information about the speaker, please visit http://cancer.ucsf.edu/people/profiles/munster_pamela.3449.

Activity Description

NCI’s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and are approved by the CCR Office of the Director. Lectures occur every Friday from 12:00 to 1:00 p.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus from September through June, with exceptions around holidays and major cancer meetings. The lecture schedule is posted on various calendars of events, including at the following link at https://ccrod.cancer.gov/confluence/display/CCRGREL/Home.

This event will be available via  NIH VideoCast.

Continuing Education Credits: [CME] [1]

CME Activity Code

24564

Who Should Attend?

NIH scientists, clinicians and fellows

Educational Objectives

This event will be available via  NIH VideoCast.

Continuing Education Credits: [CME] [1]

After attending this activity, the participant will demonstrate the ability to:

  • Recognize current challenges in the approach and treatment of germline mutation carriers.
  • Identify alternative strategies in the management of hereditary cancer.
  • Define the opportunities of targeting DNA damaging repair pathways.

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The Johns Hopkins University School of Medicine designates this live activity for 1 credit per session for a maximum of 52 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Speaker and Provider Disclouse

It is the policy of the Johns Hopkins School of Medicine that the speaker and provider globally disclose real or apparent conflicts of interests, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity materials.

Full Disclosure Policy Affecting CME Activities

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

  1. Planning committee members Drs. Frederic Barr, Yamini Dalal, Romina Goldszmid, Tim Greten, Stanley Lipkowitz, Adam Sowalsky, and Sandra Wolin report they have no relevant relationships to this educational presentation.
  2. Dr. Pamela Munster, the speaker for this activity, reports that she has no relevant financial information to disclose.

Off-label Product Discussion

Dr. Munster reports that she will not be discussing unlabeled, investigational, or alternative uses of a product, device, or technique.

Reasonable Accommodation

Individuals with disabilities who need Sign Language Interpreters and/or reasonable accommodation to participate in this event should contact Romi Sawhney, at (240) 760-6400, and/or the Federal Relay Service (1-800-877-8339). Requests should be made at least two business days in advance of the event.

Contacts for this Event

Romi Sawhney
Email: sawhneyr@mail.nih.gov
Phone: (240) 760-7756

Julia Lam
Email: julia.lam@nih.gov
Phone: (301) 846-6957

Date and Time: 

Fri, 02/07/2020 - 12:00 - 13:00

Location: 

NIH Main Campus, Lipsett Amphitheater, Building 10, Bethesda, MD

Speaker(s): 

Pamela Munster, MD

Sponsor(s): 

CCR Grand Rounds lecture series